NCR1 and neoplasm: Further, dual treatment with both CD155 and CD73 blocking antibodies had increased intracranial tumor infiltrates of NKp46+GzB+ NK cells and CD3 + T cells, without significant upregulation of PD-1 + T cells, LAG-3 or FoxP3+ Tregs, further justifying targeting of both tumor antigens (Fig. 4D–G, Supplementary Figs. 10–11).